phenytoin has been researched along with Anterior Optic Neuritis in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized trial of phenytoin in acute optic neuritis (ON) demonstrated a 30% reduction in retinal nerve fiber layer (RNFL) loss with phenytoin versus placebo." | 9.41 | Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis. ( Altmann, DR; Blennow, K; Giovannoni, G; Gnanapavan, S; Grant, D; Hickman, SJ; Kapoor, R; Kuhle, J; Leppert, D; Raftopoulos, R; Zetterberg, H, 2021) |
| "Phenytoin has been shown to reduce the peripapillary retinal nerve fiber layer (pRNFL) loss in optic neuritis (ON)." | 9.34 | Effect of phenytoin on retinal ganglion cells in acute isolated optic neuritis. ( Aghsaei Fard, M; Ghahvehchian, H; Gholizade, A; Yadegari, S, 2020) |
| " Patients with acute optic neuritis aged 18-60 years, presenting within 2 weeks of onset, with visual acuity of 6/9 or worse, were randomly assigned (1:1) by minimisation via a web-based service to oral phenytoin (maintenance dose 4 mg/kg per day if randomised before or on July 16, 2013, and 6 mg/kg per day if randomised on or after July 17, 2013) or placebo for 3 months, stratified by time from onset, centre, previous multiple sclerosis diagnosis, use of disease-modifying treatment, and use of corticosteroids for acute optic neuritis." | 9.22 | Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. ( Altmann, DR; Gandini Wheeler-Kingshott, CA; Giovannoni, G; Hickman, SJ; Hoggard, N; Kapoor, R; Koltzenburg, M; Malladi, P; Mallik, S; Miller, DH; Paling, D; Raftopoulos, R; Sarrigiannis, PG; Schmierer, K; Sharrack, B; Sheridan, R; Toosy, A; Yiannakas, MC, 2016) |
| "A randomized trial of phenytoin in acute optic neuritis (ON) demonstrated a 30% reduction in retinal nerve fiber layer (RNFL) loss with phenytoin versus placebo." | 5.41 | Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis. ( Altmann, DR; Blennow, K; Giovannoni, G; Gnanapavan, S; Grant, D; Hickman, SJ; Kapoor, R; Kuhle, J; Leppert, D; Raftopoulos, R; Zetterberg, H, 2021) |
| "Phenytoin has been shown to reduce the peripapillary retinal nerve fiber layer (pRNFL) loss in optic neuritis (ON)." | 5.34 | Effect of phenytoin on retinal ganglion cells in acute isolated optic neuritis. ( Aghsaei Fard, M; Ghahvehchian, H; Gholizade, A; Yadegari, S, 2020) |
| " Patients with acute optic neuritis aged 18-60 years, presenting within 2 weeks of onset, with visual acuity of 6/9 or worse, were randomly assigned (1:1) by minimisation via a web-based service to oral phenytoin (maintenance dose 4 mg/kg per day if randomised before or on July 16, 2013, and 6 mg/kg per day if randomised on or after July 17, 2013) or placebo for 3 months, stratified by time from onset, centre, previous multiple sclerosis diagnosis, use of disease-modifying treatment, and use of corticosteroids for acute optic neuritis." | 5.22 | Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. ( Altmann, DR; Gandini Wheeler-Kingshott, CA; Giovannoni, G; Hickman, SJ; Hoggard, N; Kapoor, R; Koltzenburg, M; Malladi, P; Mallik, S; Miller, DH; Paling, D; Raftopoulos, R; Sarrigiannis, PG; Schmierer, K; Sharrack, B; Sheridan, R; Toosy, A; Yiannakas, MC, 2016) |
| "Phenytoin is a non-sedative barbiturate derivate and has been recently rediscovered as a neuroprotective and retinoprotective compound in patients affected by optic neuritis secondary to multiple sclerosis." | 4.98 | The retinoprotective role of phenytoin. ( Bartollino, S; Chiosi, F; Costagliola, C; di Staso, S; Hesselink, JMK; Pascotto, A; Rinaldi, M; Uva, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (45.45) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Yadegari, S | 1 |
| Gholizade, A | 1 |
| Ghahvehchian, H | 1 |
| Aghsaei Fard, M | 1 |
| Raftopoulos, R | 2 |
| Kuhle, J | 1 |
| Grant, D | 1 |
| Hickman, SJ | 2 |
| Altmann, DR | 2 |
| Leppert, D | 1 |
| Blennow, K | 1 |
| Zetterberg, H | 1 |
| Kapoor, R | 2 |
| Giovannoni, G | 2 |
| Gnanapavan, S | 1 |
| Chiosi, F | 2 |
| Keppel Hesselink, J | 1 |
| Rinaldi, M | 2 |
| Di Staso, S | 2 |
| Bartollino, S | 2 |
| Costagliola, C | 2 |
| Uva, M | 1 |
| Pascotto, A | 1 |
| Hesselink, JMK | 1 |
| Saidha, S | 1 |
| Calabresi, PA | 1 |
| Toosy, A | 1 |
| Sharrack, B | 1 |
| Mallik, S | 1 |
| Paling, D | 1 |
| Yiannakas, MC | 1 |
| Malladi, P | 1 |
| Sheridan, R | 1 |
| Sarrigiannis, PG | 1 |
| Hoggard, N | 1 |
| Koltzenburg, M | 1 |
| Gandini Wheeler-Kingshott, CA | 1 |
| Schmierer, K | 1 |
| Miller, DH | 1 |
| Addington, WW | 1 |
| Igata, A | 1 |
| Podos, SM | 2 |
| Keltner, JL | 2 |
| Becker, B | 1 |
| Gay, AJ | 1 |
| Ellenberger, C | 1 |
| Burde, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis[NCT01451593] | Phase 2 | 92 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for phenytoin and Anterior Optic Neuritis
| Article | Year |
|---|---|
The retinoprotective role of phenytoin.
Topics: Antineoplastic Agents; Drug Discovery; Enzyme Inhibitors; Humans; Multiple Sclerosis; Neuroprotectiv | 2018 |
[Ataxia associated with infections and toxicosis].
Topics: Abdomen; Adult; Animals; Ataxia; Cerebellar Ataxia; Cerebrovascular Disorders; Demyelinating Disease | 1971 |
Glaucoma.
Topics: Acid-Base Equilibrium; Animals; Contact Lenses, Hydrophilic; Delayed-Action Preparations; Glaucoma; | 1973 |
4 trials available for phenytoin and Anterior Optic Neuritis
| Article | Year |
|---|---|
Effect of phenytoin on retinal ganglion cells in acute isolated optic neuritis.
Topics: Humans; Optic Neuritis; Phenytoin; Retina; Retinal Ganglion Cells; Tomography, Optical Coherence | 2020 |
Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis.
Topics: Biomarkers; Humans; Intermediate Filaments; Neurofilament Proteins; Neuroprotection; Optic Neuritis; | 2021 |
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Optic Neuriti | 2016 |
Acute optic neuropathy. Treatment with diphenylhydantoin.
Topics: Administration, Oral; Adult; Aged; Capsules; Female; Humans; Ischemia; Male; Middle Aged; Optic Nerv | 1974 |
4 other studies available for phenytoin and Anterior Optic Neuritis
| Article | Year |
|---|---|
Phenytoin: its potential as neuroprotective and retinoprotective drug.
Topics: Animals; Anticonvulsants; Humans; Neuroprotective Agents; Optic Neuritis; Phenytoin; Retina | 2018 |
Phenytoin in acute optic neuritis: neuroprotective or not?
Topics: Female; Humans; Male; Neuroprotective Agents; Optic Neuritis; Outcome Assessment, Health Care; Pheny | 2016 |
The side effects and interactions of antituberculosis drugs.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Central Nervous System Diseases; Chemical and Dru | 1979 |
Effect of diphenylhydantoin in ischemic optic neuritis.
Topics: Adult; Aged; Eye; Female; Fixation, Ocular; Follow-Up Studies; Humans; Ischemia; Kinetics; Male; Mid | 1972 |